PCAS NET SALES AS AT DECEMBER 31, 2016
Longjumeau, January 31, 2017
PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as at December 31, 2016.
The PCAS Group had generated consolidated net sales of €192.0 million as at December 31, 2016, representing growth of +7.2% compared to the same period of the previous financial year (+6.5% at a constant exchange rate).
| In millions of Euros | 2016 | 2015 | Growth in % | 2016 At a constant exchange rate | Growth in % | |||||
| Net sales at December 31 | 192.0 | 179.1 | 7.2% | 190.7 | 6.5% | |||||
| Pharmaceutical synthesis | 130.0 | 120.8 | 7.6% | 128.8 | 6.6% | |||||
| Fine specialty chemicals | 62.0 | 58.3 | 6.4% | 61.9 | 6.2% |
Vincent Touraille, Chief Executive Officer of PCAS, explains: "Net sales increased in 2016, both in Pharmaceutical Synthesis and Fine Specialty Chemicals. The Group's Current Operating Income should be slightly higher than in 2015, bearing, as expected, additional expenses incurred by the introduction of a new industrial organization to cope with a sustained increase in activity. Net income is also likely to be up compared to 2015 (restated to reflect the effect of €2.9 million of insurance revenue net of tax)".
Pharmaceutical Synthesis (67.7%)
The Pharmaceutical Synthesis business generated €130.0 million, up +7.6% on 2015 (+6.6% at a constant exchange rate), which was especially driven by the Exclusive activity.
Fine Specialty Chemicals (32.3%)
Net sales of Fine Specialty Chemicals amounted to €62.0 million, up 6.4% on 2015 (+6.2% at a constant exchange rate), with growth in both Performance Additives and Advanced Specialty Chemicals.
| NEXT FINANCIAL DISCLOSURE: | |
| 2016 results, on February 21, 2017 |
ABOUT PCAS
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups.
To find out more about PCAS, visit: www.pcas.com
| PCAS | NewCap |
| Vincent Touraille / Eric Moissenot PCAS | Emmanuel Huynh / Louis-Victor Delouvrier NewCap Financial communication and Investor Relations |
| Tel. : +33 1 69 79 61 32 www.pcas.com | Tel. : +33 1 44 71 98 53 pcas@newcap.eu |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCAS via Globenewswire
